1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 21 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2007Cetuximab for the treatment of colorectal cancerJonker, D.; O'Callaghan, C.; Karapetis, C.; Zalcberg, J.; Tu, D.; Au, H.; Berry, S.; Krahn, M.; Price, T.; Simes, R.; Tebbutt, N.; van Hazel, G.; Wierzbicki, R.; Langer, C.; Moore, M.
2021Pre- And postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCDSchmoll, H.J.; Stein, A.; van Cutsem, E.; Price, T.; Hofheinz, R.D.; Nordlinger, B.; Daisne, J.F.; Janssens, J.; Brenner, B.; Reinel, H.; Hollerbach, S.; Caca, K.; Fauth, F.; Hannig, C.V.; Zalcberg, J.; Tebbutt, N.; Mauer, M.E.; Marreaud, S.; Lutz, M.P.; Haustermans, K.
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
2013Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC clinical trials group and AGITG co.Siu, L.; Shapiro, J.; Jonker, D.; Karapetis, C.; Zalcberg, J.; Simes, J.; Couture, F.; Moore, M.; Price, T.; Siddiqui, J.; Nott, L.; Charpentier, D.; Liauw, W.; Sawyer, M.; Jefford, M.; Magoski, N.; Haydon, A.; Walters, I.; Ringash, J.; Tu, D.; et al.
2013The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumorsRosen, L.; Lipton, L.; Price, T.; Belman, N.; Boccia, R.; Hurwitz, H.; Stephenson Jr, J.; Wirth, L.; McCoy, S.; Hei, Y.; Hsu, C.; Tebbutt, N.
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerPrice, T.; Bruhn, M.; Lee, C.; Hardingham, J.; Townsend, A.; Mann, K.; Simes, J.; Weickhardt, A.; Wrin, J.; Wilson, K.; Gebski, V.; Van Hazel, G.; Robinson, B.; Cunningham, D.; Tebbutt, N.
2013Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapyPadman, S.; Padbury, R.; Beeke, C.; Karapetis, C.; Bishnoi, S.; Townsend, A.; Maddern, G.; Price, T.
2014Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South AustraliaHocking, C.; Broadbridge, V.; Karapetis, C.; Beeke, C.; Padbury, R.; Maddern, G.; Roder, D.; Price, T.
2012Impact of age on choice of chemotherapy and outcome in advanced colorectal cancerKhattak, M.; Townsend, A.; Beeke, C.; Karapetis, C.; Luke, C.; Padbury, R.; Maddern, G.; Roder, D.; Price, T.
2007Treatment and survival from breast cancer: The experience of patients at South Australian teaching hospitals between 1977 and 2003Luke, C.; Gill, P.; Birrell, S.; Humeniuk, V.; Borg, M.; Karapetis, C.; Koczwara, B.; Olver, I.; Penniment, M.; Pittman, K.; Price, T.; Walsh, D.; Yeoh, E.; Roder, D.

Discover